LL-37

Antimicrobial peptide (cathelicidin) · Also known as Cathelicidin, hCAP18 active fragment

What is ll-37?

The only human cathelicidin antimicrobial peptide, a 37-amino-acid peptide that serves as a frontline component of innate immune defense. It directly kills bacteria, viruses, and fungi while also modulating immune and inflammatory responses.

LL-37 is the active fragment of the human cathelicidin precursor protein hCAP18 and plays a critical role in the body’s first line of defense against infection. It has demonstrated potent antimicrobial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains like MRSA and VRE, as well as antiviral and antifungal properties. Beyond direct pathogen killing, LL-37 promotes wound healing and modulates inflammatory responses. While it is a naturally occurring peptide with extensive in vitro and animal research, clinical application of synthetic LL-37 is still in early stages.

Key takeaway: LL-37 is the human body’s own antimicrobial peptide with broad-spectrum pathogen-killing ability, though its therapeutic use as an injectable remains investigational.

Benefits & evidence

Antimicrobial defense High confidence
Anti-biofilm activity Moderate confidence
Wound healing support Moderate confidence
Immune cell recruitment Moderate confidence
Anti-inflammatory modulation Preliminary confidence

How it works

LL-37 carries a strong positive charge that attracts it to the negatively charged membranes of bacteria and other pathogens. Once it contacts a microbial membrane, its alpha-helical structure allows it to insert into and physically disrupt the membrane, essentially punching holes in the pathogen and killing it. This mechanism makes it effective against a broad range of organisms, including antibiotic-resistant strains, and makes it difficult for bacteria to develop resistance.

Beyond direct antimicrobial action, LL-37 functions as an immune signaling molecule. It acts as a chemoattractant, recruiting immune cells like neutrophils, monocytes, and T cells to sites of infection. It also modulates inflammation by neutralizing bacterial lipopolysaccharide (LPS) and stimulates wound healing by promoting cell migration and angiogenesis.

Dosing information

Typical dosing protocol
Starting dose

50-100 mcg/day

Week 1
Maintenance dose

100-200 mcg/day

2-4 week cycles, 5 days on / 2 days off

Administered subcutaneously. May cause localized burning or redness at injection site due to its cationic charge. Not FDA-approved; dosing based on practitioner protocols.

Side effects

Most side effects tend to improve as your body adjusts.

Injection site pain/burning Common
Local redness or swelling Common
Headache Uncommon
Fatigue Uncommon
Cytotoxicity at high doses Rare

Research (10 studies)